A new study has explored how compounds derived from cobra venom could be used to design next-generation antimicrobial peptides, offering a potential new direction in the search for antibiotics.
Researchers used computational tools and machine learning models to analyze cardiotoxins from cobra species (Naja) and identify peptide fragments with possible antibacterial properties. These venom proteins naturally interact with cell membranes, making them useful templates for drug discovery.
From this analysis, 14 candidate peptides were selected, synthesized, and tested in laboratory conditions. The study combined AI-based prediction tools, structural modeling, and experimental validation to assess antibacterial activity and toxicity.
Laboratory testing showed that only a subset of the designed peptides had measurable antibacterial effects. One peptide, CTX-p5, demonstrated the strongest activity against both Gram-positive and Gram-negative bacteria by disrupting bacterial membranes, increasing permeability and causing membrane depolarization.
However, the overall potency of the peptides remained limited compared with clinically established antimicrobial compounds. Most candidates required relatively high concentrations to achieve effects, and several showed little or no antibacterial activity.
Researchers also evaluated safety, finding that most peptides had low to moderate toxicity toward human red blood cells, although some showed higher hemolytic activity at increased doses.
The study highlights both the promise and limitations of using AI-assisted venom mining for drug discovery. While machine learning tools helped rapidly identify candidates, their predictive accuracy varied, and experimental testing remained essential to confirm real-world activity.
Scientists conclude that venom-derived scaffolds, combined with improved AI modeling and experimental refinement, could help guide the development of new antimicrobial agents, particularly as antibiotic resistance continues to rise globally.
However, the research remains early-stage, and further optimization is needed before any of these peptides can be considered viable therapeutic leads.